GemPharmatech Co

GemPharmatech Co Acquisitions (Net)

The Acquisitions (Net) of GemPharmatech Co (688046.SS) as of Oct 21, 2026 is 272.57 M CNY. In the previous year, Acquisitions (Net) was 187.29 M CNY — a change of 45.54% (higher).

Acquisitions (Net)

272.57 MCNY

YoY

45.54%

Last updated:

Acquisitions (Net) of GemPharmatech Co is 2024 272.57 M CNY. Acquisitions (Net) of GemPharmatech Co was 2023 187.29 M CNY. It decreases by 45.54% higher compared to the previous year.

The GemPharmatech Co Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2018
-30.00 M CNY
Jan 1, 2019
5.38 M CNY
Jan 1, 2020
33.96 M CNY
Jan 1, 2021
-264.66 M CNY
Jan 1, 2022
-804.35 M CNY
Jan 1, 2023
187.29 M CNY
Jan 1, 2024
272.57 M CNY
The GemPharmatech Co Acquisitions (Net) history
YEARAcquisitions (Net)YoY
272.57 MCNY+45.54%
187.29 MCNY-123.28%
-804.35 MCNY+203.92%
-264.66 MCNY-879.31%
33.96 MCNY+531.16%
5.38 MCNY-117.94%
-30.00 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GemPharmatech Co Stock analysis

What does GemPharmatech Co do? GemPharmatech Co., Ltd. generates revenue through the research and development, manufacturing, and sale of experimental mouse models. The company utilizes gene-editing and other technologies to produce these models, which are primarily sold to satisfy experimental demands in gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental research areas. Customized model breeding, drug efficacy analysis, and model customization services are also key revenue streams, targeting institutions engaged in biomedical research and pharmaceutical development. The company's products and services are tailored for clients in the fields of gene function cognition, disease mechanisms analysis, and drug target discovery. These clients include research institutions and pharmaceutical companies requiring specialized mouse models for preclinical studies and drug development. The firm's focus on gene-editing technologies enables it to provide high-quality, customized solutions that meet specific research needs. GemPharmatech's business model centers on providing innovative solutions for experimental research through its proprietary gene-editing technologies. By offering both standard and customized mouse models alongside related services, the company addresses the growing demand for precise and efficient research tools in the pharmaceutical and biotechnology sectors. The firm's revenue streams are directly tied to the sale of these models and the provision of specialized services to clients in the biomedical research industry. GemPharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GemPharmatech Co stock

Acquisitions (Net) of GemPharmatech Co is 272.57 M CNY in 2024.

Acquisitions (Net) of GemPharmatech Co changed from 187.29 M CNY to 272.57 M CNY, representing a 45.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) GemPharmatech Co since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s GemPharmatech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — GemPharmatech Co

All Key Metrics — GemPharmatech Co